Method of diagnosis and treatment and related compositions and apparatus

• US 6,258,032 B1
• Filed: 07/13/1998
• Issued: 07/10/2001
• Est. Priority Date: 01/29/1997
• Status: Expired due to Fees

• Current Assignee: William M. Hammesfahr
• Original Assignee: William M. Hammesfahr
• Inventors: Hammesfahr, William M.
• Primary Examiner(s): Jaworski, Francis J.
• Application Number:
  US09/101,934
• Time in Patent Office: 1,093 Days
• Field of Search: 600/453-456, 600/437, 600/504-507, 604/21, 604/30, 604/31, 604/49-50
• US Class Current: 600/454
• CPC Class Codes: A61B 5/369 Electroencephalography [EEG] devices for psychotechnics A61B5/16
• CPC Class Codes: A61B 5/372 Analysis of electroencephalograms
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61B 8/06 Measuring blood flow measuring volume flow in general G01F, e.g. G01F1/66, G01F1/72; measuring speed of fluids in general G01P5/00
• CPC Class Codes: A61K 31/15 Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
• CPC Class Codes: A61K 31/21 Esters, e.g. nitroglycerine, selenocyanates
• CPC Class Codes: A61K 31/4168 having a nitrogen attached in position 2, e.g. clonidine
• CPC Class Codes: A61K 31/4422 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Abstract

A method for treatment of a disease comprising vasospasm or other symptom alleviable by smooth muscle relaxation and a vasodilator delivery system. The figure is a TCD of MCA post nitroglycerine spray obtained during continuous monitoring.

Claims

1. A method of operating a titration system for the treatment of chronic noncardiac diseases comprising vasospasm or other symptom alleviatable by smooth muscle relaxation, said system comprising a flow device and a dosage device and said method comprising in combination:

a) operating the flow device to measure blood flow in at least one area,

b) applying the dosage device for administering a first dosage of a vasodilator,

c) operating the flow device for remeasuring blood flow, and;

d) reapplying the dosage device to administer an adjusted further dosage of a vasodilator, the further dosage being adjusted in response to said remeasured blood flow,

e) repeating the operation of said system over a period of days while titrating said dosage according to still further measurements of blood flow to maintain optimal blood flow velocity.

2. A method according to claim 1 wherein the symptoms comprise cerebral vasospasm.

3. A method according to claim 1 wherein the measuring device utilizes a technique selected from the group consisting of Transcranial Doppler (TCD), quantitative electroencephalogram and determining relative vessel diameter.

4. A method according to claim 1 wherein the flow device measures blood flow as Mean Fluid Velocity (MFV) in at least one intracranial vessel.

5. A method according to claim 4 wherein the MFV rises above about 0.4 meters/minute during vasospasms.

6. A method according to claim 1 wherein the treatment is continued for from about 5 to 250 weeks.

7. A method according to claim 1 wherein the vasodilator is selected from the group consisting of Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, such as p.o. clonidine, Dynacirc (istadipine), hydrazine, nifedipine, and medicines from the empirical group combinations of the foregoing.

8. A method according to claim 1 wherein the disease is selected from the group consisting of whiplash, closed head injury with vasospasm, attention deficit disorder with vasospasm, migraine with inter-octal evidence of vasospasm, syncope or blackout spells of unknown actiology with evidence of vasospasm, seizure with evidence of vasospasm, and dementia with evidence of vasospasm, concussion and post-concussion syndrome with evidence of vasospasm, migraine, sympathetic vasospasm associated with breast implants, and cerebral vasospasm. fibromyalgia, gastric disorders and other systemic disorders, psychosis, other psychiatric disease, attention deficit disorder and systemic disorders dyslexia, memory disturbances, depression, psychosis, reflex sympathetic dystrophy, mood disorders and sensory motor disorders;

transient ischemic attack (TIA), pseudoseizure, hemibalism, and stroke;

tremor, Parkinson'"'"'s disease, torticollis, electrical shock trauma, attention deficit disorder, concussion and post concussion syndrome, comprising vasospasm as a component.

9. A method of claim 1 wherein the patient treated presents with transient or continuous TCD Mean Flow Velocities (MFV) of greater than 0.1 meter per second.

11. A method of claim 1 wherein the treatment is applied to a patient who presents with transient or continuous TCD Mean Flow Velocities (MFV) of greater than 0.3 meters per second.

12. A method according to claim 1 wherein the disease is selected from the group consisting of fibromyalgia, gastric disorders and other systemic disorders, psychosis, other psychiatric disease, attention deficit disorder and systemic disorders, comprising vasospasm as a component.

13. A method according to claim 1 wherein the disease is selected from the group consisting of systemic disorders comprising vasospasm as a component.

10. A method of treatment of intracranial vasospasms comprising intermittently applying a vasodilator and measuring transcranial doppler mean flow velocity, and titrating dosage as the vasospasms reduce in frequency and/or severity.

14. A method for operating a titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination:

operating a flow device to test for the presence of a continued diastolic flow beyond end diastolic velocity as an indication of vasospasm, applying a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, reoperating said flow device for testing over time and adjusting said dosage device to titrate said dosage to minimize occurrence and severity of said indications of vasospasm.